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Abstract Epidermal growth factor (EGF), insulin-like growth
factor 1 (IGF1) and phorbol myristate acetate (PMA) induce the
inhibition of glycogen synthase kinase 3 (GSK3) by stimulating
the phosphorylation of an N-terminal serine. Here, we show that
protein kinase B (PKB) plays a key role in mediating EGF-
induced inhibition of GSK3K and that the classical MAP kinase
(MAPK) cascade has two functions in this process. Firstly, it
makes a transient contribution to EGF-induced inhibition of
GSK3K. Secondly, it shortens the duration of PKB activation
and GSK3K inhibition. In contrast, PKB alone mediates the
IGF1-induced inhibition of GSK3K, while the MAPK cascade
mediates the inhibition of GSK3K by PMA.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Glycogen synthase kinase 3 (GSK3) is a protein kinase that
is thought to play multiple roles in cell regulation. For exam-
ple, it phosphorylates and inhibits both glycogen synthase [1]
and protein synthesis initiation factor eIF2B [2], which are
likely to underlie, at least in part, the insulin-induced stimu-
lation of glycogen synthesis [3^5] and protein synthesis [6].
Inhibition of GSK3 may also underlie the insulin or insulin-
like growth factor 1 (IGF1)-induced dephosphorylation of the
microtubule-associated protein Tau in cultured hippocampal
neurones [7]. The inhibition of GSK3 has been suggested to
underlie the phorbol ester-induced dephosphorylation of the
transcription factor c-Jun, at sites that lie proximal to the
DNA binding domain [8], and to play a role in growth fac-
tor-induced protection against apoptosis [9].
The inhibition of GSK3 by insulin [10], growth factors [11]
and phorbol myristate acetate (PMA) [12] results from the
phosphorylation of GSK3 at a N-terminal serine residue
(Ser-21 in GSK3K, Ser-9 in GSK3L) and three protein kinases
(protein kinase B (PKB) [10], MAP kinase (MAPK)-activated
protein kinase 1 (MAPKAP-K1, also called p90rsk) and p70
S6 kinase (p70 S6K)) [13,14], that become activated in re-
sponse to one or more of these signals, phosphorylate these
residues in vitro. The insulin- or IGF1-induced inhibition of
GSK3 is prevented by inhibitors of phosphatidylinositol (PI)
3-kinase (wortmannin or LY294002) that block the activation
of PKB (also called c-Akt), but not by inhibitors of the acti-
vation of p70 S6K (rapamycin) or MAPKAP-K1 (PD98059)
[10]. Moreover, cell transfection experiments using a domi-
nant negative mutant of PKB support the view that PKB is
likely to mediate the inhibition of GSK3 by insulin [15].
The inhibition of GSK3 by epidermal growth factor (EGF)
is una¡ected by rapamycin [16] and evidence has been pre-
sented that this e¡ect is mediated by MAPKAP-K1. Thus,
GSK3L becomes phosphorylated at Ser-9 when co-transfected
with MAPKAP-K1 [12] and the EGF-induced inhibition of
GSK3 is largely suppressed in a cell line overexpressing a
catalytically inactive mutant of MAPK kinase 1 (MKK1,
also called MEK) [17], an enzyme that lies ‘upstream’ of
MAPKAP-K1 in the classical MAPK cascade. In addition,
the EGF-induced inhibition of GSK3 is enhanced in cells ex-
pressing a MKK1 mutant which displays some constitutive
activity [17]. Moreover, in cells overexpressing MAPKAP-
K1, the phosphorylation of GSK3L at Ser-9 is stimulated by
PMA, which is known to trigger activation of the MAPK
cascade, but not the activation of PKB [18].
The acute regulation of GSK3 activity by EGF and PMA
was studied before the advent of inhibitors that are capable of
preventing activation of the MAPK cascade. The advantage
of using such small cell permeant protein kinase inhibitors
(reviewed in [19]) is that they can be used to study the roles
of protein kinases without the need for overexpression of
active or inactive forms of protein kinases, which can lead
to erroneous conclusions. We have therefore used two struc-
turally distinct inhibitors of the MAPK cascade, namely
PD98059 (which prevents the activation of MKK1 [20]) and
U0126 (which inhibits MKK1 [21]), in conjunction with two
PI 3-kinase inhibitors (wortmannin and LY294002) and rapa-
mycin, to identify the signalling pathways that mediate the
EGF-induced inhibition of GSK3. In contrast to earlier re-
ports, we ¢nd that a PI 3-kinase-dependent pathway, prob-
ably mediated by PKB, plays a major role in this process and
that the MAPK cascade plays two distinct roles. Firstly, it
contributes, albeit very transiently, to the inhibition of
GSK3. Secondly, it controls the duration of inhibition of
GSK3 by PKB.
2. Materials and methods
2.1. Materials
IGF1 and EGF were purchased from Gibco BRL (Paisley, UK),
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PMA and wortmannin from Sigma Chemical (Poole, UK), rapamy-
cin, LY294002, PD98059 and U0126 from Calbiochem (Nottingham,
UK) and protein G-Sepharose from Pharmacia (Milton Keynes, UK).
Immunoprecipitating antibodies speci¢c for PKBQ [22] and MAP-
KAP-K1 [23] were raised in sheep and a⁄nity-puri¢ed on CH-Sephar-
ose columns to which the appropriate peptide antigen was coupled
covalently. Further antibodies were raised in sheep that recognise
GSK3K phosphorylated at Ser-21 and that recognise dephosphoryl-
ated and phosphorylated GSK3 equally well. These antibodies were
raised against the peptides RARTSS*FAEPG (residues 16^26 of
GSK3K, where * denotes a phosphorylated residue) and QAP-
DATPTLTNSS (residues 471^483 of human GSK3K) and a⁄nity-pu-
ri¢ed as described above. All four antibodies can be purchased from
UBI (Lake Placid, NY, USA).
2.2. Cell culture, stimulation and cell lysis
Mouse Swiss 3T3 ¢broblasts were cultured to con£uence [20] and
incubated for 16 h in Dulbecco’s modi¢ed Eagles medium from which
foetal calf serum was omitted. Cells were stimulated for the times
indicated with IGF1, EGF or PMA with or without prior treatment
for 10 min with wortmannin (100 nM), LY294002 (100 WM) or rapa-
mycin (100 nM), or for 1 h with PD98059 (50 WM) or U0126 (10 WM).
In experiments where cells were pretreated with wortmannin and ei-
ther PD98059 or U0126, wortmannin was added for the last 10 min of
the pre-incubation only. The cells were lysed in 1.0 ml of 50 mM Tris-
HCl (pH 7.5), 1% (w/v) Triton X-100, 1 mM EDTA, 1 mM EGTA, 50
mM NaF, 10 mM sodium L-glycerophosphate, 5 mM sodium pyro-
phosphate, 1 mM sodium orthovanadate, 1 WM microcystin-LR, 0.1%
(by volume) 2-mercaptoethanol, 1 mM benzamidine and 0.2 mM
phenylmethylsulphonyl £uoride, frozen immediately in liquid nitrogen
and stored at 380‡C. Protein concentrations were determined accord-
ing to Bradford [24] using bovine serum albumin as a standard.
2.3. Immunoprecipitation and assay of PKB and MAPKAP-K1
PKBQ [22] and MAPKAP-K1 [23] were immunoprecipitated from
100 and 50 Wg of cell lysate, respectively, and assayed using the pep-
tide GRPRTSSFAEG, termed Crosstide [10,21,25]. One unit of activ-
ity (U) was de¢ned as that amount which catalysed the phosphoryla-
tion of 1 nmol substrate in 1 min.
2.4. Immunoblotting of GSK3K
Cell lysates (40 Wg) were denatured in 1% (by mass) sodium dodecyl
sulfate (SDS), electrophoresed on 10% SDS-polyacrylamide gels,
transferred to nitrocellulose membranes and immunoblotted with ap-
propriate antibodies. Detection was performed using the enhanced
chemiluminescence reagent (Amersham).
3. Results
3.1. IGF1- and EGF-dependent activation of PKB and the
MAPK cascade in Swiss 3T3 cells
In order to study the potential roles of PKB and MAP-
KAP-K1 in the IGF1- and EGF-induced regulation of
GSK3 activity, we ¢rst examined the time course of activation
of these protein kinases after stimulation with each agonist.
The activation of PKB and MAPKAP-K1 was measured after
their immunoprecipitation from the cell lysates. In Swiss 3T3
Fig. 1. Activation of PKBQ and MAPKAP-K1 by IGF1 and EGF in Swiss 3T3 cells. Cells were stimulated with 100 ng/ml IGF1 (open circles)
or 100 ng/ml EGF (closed circles) for the times indicated and PKBQ (A) or MAPKAP-K1 (B) immunoprecipitated from the cell lysates and as-
sayed as described in Section 2. The open triangles show further experiments in which the cells were incubated for 1 h with U0126 prior to
stimulation with EGF. The results shown are presented as S.E.M. for ¢ve separate experiments. Immunoprecipitations were carried out in du-
plicate in each experiment.
Fig. 2. Phosphorylation of GSK3K at Ser-21 in response to IGF1 or EGF in Swiss 3T3 cells. Cells were stimulated with 100 ng/ml IGF1 (A)
or 100 ng/ml EGF (B) for the times indicated and the phosphorylation of GSK3K at Ser-21 was examined by immunoblotting with an anti-
body that only recognises the Ser-21-phosphorylated enzyme (pGSK3K) (see Section 2). The lysates were also immunoblotted with an antibody
that does not distinguish between the phosphorylated and dephosphorylated proteins (GSK3). GSK3K migrated between bovine serum albumin
(66 kDa) and ovalbumin (43 kDa) with an apparent molecular mass of 51 kDa as expected. Similar results were obtained in three separate ex-
periments.
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cells, we found that PKBK and PKBQ were both activated by
IGF1. The activation of both isozymes occurred with a half
time of about 1 min and was maximal after 5 min. There was
no activation of PKBL (data not shown). Since PKBQ ac-
counted for almost 80% of the total PKB activity in the cell
lysates, the activity of this isoform was measured in all sub-
sequent experiments. The MAPKAP-K1 antibody used in our
experiments immunoprecipitates both MAPKAP-K1 isoforms
(MAPKAP-K1a/RSK1 and MAPKAP-K1b/RSK2).
IGF1 triggered a strong and sustained activation of PKBQ,
whereas activation by EGF was weaker and very transient
(Fig. 1A). As expected from studies in other cells, the activa-
tion of PKBQ by either agonist was abolished by pretreatment
of the cells with the PI 3-kinase inhibitors wortmannin or
LY294002 (data not shown). In contrast, both IGF1 and
EGF triggered a transient activation of MAPKAP-K1, a
downstream component of the classical MAPK cascade,
although activation induced by IGF1 was much weaker
(Fig. 1B). As expected, the activation of MAPKAP-K1 by
either EGF (Fig. 1B) or IGF1 (data not shown) was abolished
by U0126 (Fig. 1B) or PD98059 (data not shown), the speci¢c
inhibitors of the MAPK cascade. The immunosuppressant
drug rapamycin, an inhibitor of mTOR that prevents the
IGF- or EGF-induced activation of p70 S6K, had no e¡ect
on the activation of PKB by either agonist (data not shown).
3.2. EGF- and IGF1-induced phosphorylation of GSK3K at
Ser-21
It has been shown previously that GSK3K and GSK3L are
completely inactivated by the phosphorylation of Ser-21 and
Ser-9, respectively [13,14], and that IGF1-induced inhibition
in cells is accompanied by the phosphorylation of these and
no other sites [10]. Moreover, IGF1 is unable to induce any
inhibition of a GSK3L mutant in which Ser-9 has been mu-
tated to Ala [26]. It is therefore possible to assess the inhib-
ition of GSK3 simply by immunoblotting cell lysates with a
phospho-speci¢c antibody that recognises the Ser-21-phos-
phorylated form of GSK3K.
Previous work has shown that IGF1 [27] and EGF [11]
both induce 50% inhibition of GSK3, which is maximal after
Fig. 3. E¡ect of speci¢c kinase inhibitors on the IGF1- and EGF-induced phosphorylation of GSK3K at Ser-21 in Swiss 3T3 cells. Cells were
stimulated for 5 min with 100 ng/ml IGF1 or for 2 or 5 min with 100 ng/ml EGF and the lysates were immunoblotted with antibodies that rec-
ognise the Ser-21-phosphorylated enzyme (pGSK3K) or with antibodies that do not distinguish between the phosphorylated and dephosphoryl-
ated forms of the enzyme (GSK3). Prior to stimulation with agonist, the cells were pretreated with wortmannin, LY294002, PD98059, U0126
or rapamycin as described in Section 2. Similar results were obtained in three separate experiments.
Fig. 4. E¡ect of combining inhibitors of PI 3-kinase and the MAPK cascade on the EGF-induced phosphorylation of GSK3K at Ser-21 in
Swiss 3T3 cells. Cells were stimulated for the times indicated with 100 ng/ml EGF and the lysates immunoblotted with antibodies that recognise
the Ser-21-phosphorylated enzyme (pGSK3K) or with antibodies that do not distinguish between the phosphorylated and dephosphorylated
forms of the enzyme (GSK3). Prior to stimulation with agonist, the cells were pretreated as described in Section 2 with wortmannin or
PD98059/U0126 or with combinations of these inhibitors as indicated. Similar results were obtained in three separate experiments.
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about 5 min. In the present study, the phosphorylation of
GSK3K at Ser-21 induced by either agonist was found to be
nearly maximal after 2 min. However, while Ser-21 phospho-
rylation stimulated by IGF1 was sustained for at least 30 min,
EGF-stimulated phosphorylation was transient and declined
to near basal levels after 15 min (Fig. 2).
The time course of Ser-21 phosphorylation in response to
EGF or IGF1 (Fig. 2) correlated with the activation of PKB
rather than with the activation of MAPKAP-K1 (Fig. 1).
Consistent with an important role for PKB, the IGF1-induced
phosphorylation of GSK3K at Ser-21 after 5 min (or at any
other time point) was prevented by prior treatment of the cells
with wortmannin or LY294002, but not by PD98059 or
U0126 (Fig. 3). The EGF-induced phosphorylation of Ser-
21 after 2 min was also prevented by wortmannin or
LY294002 and una¡ected by PD98059 or U0126 (Fig. 3B).
However, surprisingly, the EGF-induced phosphorylation of
GSK3 at Ser-21 was hardly a¡ected by inhibitors of PI 3-
kinase or of the MAPK cascade after 5 min stimulation
(Fig. 3). Statistical analysis of the immunoblotting data
from three di¡erent experiments revealed that wortmannin
inhibited EGF-induced inhibition of GSK3 by only 36 þ 2%
after 5 min, while LY294002, PD98059 and U0126 had no
statistically signi¢cant e¡ect at this time point.
One possible reason for the very weak e¡ect of PI 3-kinase
inhibitors or MAPK cascade inhibitors on the EGF-induced
phosphorylation of GSK3K at Ser-21 after 5 min was that
activation of either pathway was su⁄cient for near maximal
phosphorylation of Ser-21 at this time. If this was the case,
then, blockade of both pathways would be required to sup-
press the e¡ect of EGF. This explanation appears to be cor-
rect, because the combination of wortmannin and PD98059 or
wortmannin plus U0126 completely prevented the EGF-in-
duced phosphorylation of Ser-21 after 5 min (Fig. 4B).
Even more unexpectedly, the phosphorylation of Ser-21 was
largely inhibited by wortmannin alone after stimulation with
EGF for 10 or 15 min and pre-incubation with PD98059 or
U0126 actually enhanced the EGF-induced phosphorylation
of Ser-21 after 15 min (Fig. 4). After 15 min, the enhancement
of GSK3K phosphorylation at Ser-21 was 299 þ 13% and
373 þ 15% in the presence of PD98059 and U0126, respec-
tively ( þ S.E.M. for three experiments). These observations
led us to re-examine the EGF-induced activation of PKB in
the presence of PD98059 or U0126. These experiments re-
vealed that, in the presence of MAPK cascade inhibitors,
the activation of PKB by EGF was not nearly so transient
and remained at a much higher level after 15 min (Fig. 5).
These unexpected observations are considered further under
Section 4.
3.3. E¡ect of PMA on the phosphorylation of GSK3
As observed in other cells, PMA induced the activation of
MAPKAP-K1 (but not PKB) and this was strongly, but not
Fig. 5. Activation of PKBQ by EGF in the absence and presence of
MAPK cascade inhibitors. Cells were stimulated with 100 ng/ml
EGF (closed circles) for the times indicated and PKBQ was immuno-
precipitated from the cell lysates and assayed as described in Section
2. The triangles show further experiments in which the cells were
pre-incubated for 1 h with U0126 (open triangles) or PD98059
(closed triangles) prior to stimulation with EGF. The results shown
are presented as S.E.M. for three separate experiments. Immunopre-
cipitations were carried out in duplicate in each experiment.
Fig. 6. Activation of MAPKAP-K1 and PKBQ and phosphorylation
of GSK3K at Ser-21 by PMA in Swiss 3T3 cells. All experiments
were repeated three times with similar results. (A) Cells were stimu-
lated with 0.4 Wg/ml PMA for the times indicated and PKBQ (closed
circles) and MAPKAP-K1 (open circles) were immunoprecipitated
from the cell lysates and assayed as described in Section 2. The tri-
angles show further experiments in which the cells were pre-incu-
bated for 1 h with U0126 (open triangles) or PD98059 (closed trian-
gles) prior to stimulation with PMA. (B) The lysates from A were
immunoblotted with an antibody that recognises the Ser-21-phos-
phorylated form of GSK3K (pGSK3K). (C) Lysates from cells that
were stimulated for 15 min with 0.4 Wg/ml PMA were immunoblot-
ted as in B. Prior to stimulation with PMA, the cells were pre-incu-
bated with PD98059, U0126, PD98059 plus wortmannin, PD98059
plus LY294002, U0126 plus wortmannin or U0126 plus LY294002
as described in Section 2.
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completely, suppressed by pretreatment of the cells with
PD98059 or U0126 (Fig. 6A). PMA also induced the phos-
phorylation of GSK3K at Ser-21 and this was partially sup-
pressed by pretreatment with PD98059 or U0126 (Fig. 6B).
Pretreatment with PD98059 plus wortmannin, or U0126 plus
wortmannin, did not produce any further reduction in the
PMA-induced phosphorylation of Ser-21 (Fig. 6C).
4. Discussion
The results described in this paper con¢rm that IGF1 trig-
gers the phosphorylation and inhibition of GSK3 via a PI 3-
kinase-dependent pathway that is una¡ected by inhibitors of
the MAPK cascade or rapamycin and which is presumably
mediated by PKB. However, our results indicate that the sig-
nalling pathways that are rate-limiting for the EGF-induced
phosphorylation of GSK3K at Ser-21 vary with the time of
stimulation. A PI 3-kinase-dependent pathway (presumably
mediated by PKB) is also responsible for the phosphorylation
of GSK3K at Ser-21 after stimulation for 2 min. However,
after 5 min, a MAPK-dependent pathway (presumably medi-
ated by MAPKAP-K1), as well as the PI 3-kinase-dependent
pathway, is also capable of phosphorylating Ser-21 maxi-
mally. Thus, after 5 min, it is necessary to block both path-
ways in order to observe signi¢cant inhibition of EGF-in-
duced Ser-21 phosphorylation.
These observations are reminiscent of the tumour necrosis
factor-induced phosphorylation of the transcription factor
CREB at Ser-133 in HeLa cells. After 5 min stimulation,
Ser-133 phosphorylation can be prevented by an inhibitor of
stress-activated protein kinase 2/p38 (SAPK2/p38) but, after
15 min, CREB phosphorylation can only be blocked by in-
hibiting the classical MAPK cascade and SAPK2/p38 [28].
These observations highlight the need to use combinations
of small cell permeant inhibitors in order to deduce which
signalling pathways are rate-limiting in any particular situa-
tion.
A surprising observation was that the phosphorylation of
GSK3K at Ser-21 was again largely blocked by inhibitors of
PI 3-kinase alone, after stimulation with EGF for 10 min,
even though the activation of MAPKAP-K1 was still quite
high and the activation of PKB was declining (Fig. 1). These
observations indicate that, although active, MAPKAP-K1
loses the ability to phosphorylate GSK3 after 10 min. One
possible explanation for this ¢nding is that MAPKAP-K1 is
present in the cytosol after 5 min but, as reported previously
[29], translocates to the nucleus after 10 min, where it becomes
physically separated from the largely cytosolic GSK3. Such
compartmentalisation may account for the inability of MAP-
KAP-K1 to phosphorylate GSK3 at these later time points.
Interestingly, inhibition of the MAPK cascade actually
stimulated the PI 3-kinase-dependent phosphorylation of
GSK3 induced by EGF after 15 min (Fig. 4). This unexpected
observation was explained when the EGF-dependent activa-
tion of PKB was found to become much less transient in the
presence of inhibitors of the MAPK cascade. This implies that
the MAPK cascade controls the duration of PKB activation
after stimulation with EGF. To our knowledge, this is the ¢rst
report of ‘crosstalk’ between these two signal transduction
pathways. The point at which this ‘crosstalk’ takes place is
currently under investigation.
In summary, our results demonstrate that PKB plays a
major role in the regulation of GSK3 activity by EGF and
that the classical MAPK cascade plays two roles in this proc-
ess. Firstly, it contributes to the EGF-induced inhibition of
GSK3 after 5 min. Secondly, it controls the inactivation of
PKB and time of re-activation of GSK3 thereafter.
Acknowledgements: We thank the Biotechnology and Biological Sci-
ences Research Council and SmithKline Beecham for a CASE stu-
dentship (to M.S.) and the UK Medical Research Council, the British
Diabetic Association, The Royal Society and the Louis Jeantet Foun-
dation for ¢nancial support.
References
[1] Embi, N., Rylatt, D.B. and Cohen, P. (1980) Eur. J. Biochem.
107, 519^527.
[2] Welsh, G.I. and Proud, C.G. (1993) Biochem. J. 294, 625^629.
[3] Hughes, K., Ramakrishna, S., Benjamin, W.B. and Woodgett,
J.R. (1992) Biochem. J. 288, 309^314.
[4] Cohen, P., Alessi, D.R. and Cross, D.A.E. (1997) FEBS Lett.
410, 3^10.
[5] Alessi, D.R. and Cohen, P. (1998) Curr. Opin. Genet. Dev. 8, 55^
62.
[6] Welsh, G.I., Miller, C.M., Loughlin, A.J., Price, N.T. and Proud,
C.G. (1998) FEBS Lett. 421, 125^130.
[7] Hong, M. and Lee, V.M. (1997) J. Biol. Chem. 272, 19547^
19553.
[8] Boyle, W.B., Smeal, T., De¢ze, L.H.K., Angel, P., Woodgett,
J.R., Karin, M. and Hunter, T. (1991) Cell 64, 573^584.
[9] Pap, M. and Cooper, G.M. (1998) J. Biol. Chem. 273, 19929^
19932.
[10] Cross, D.A.E., Alessi, D.R., Cohen, P., Andjelkovich, M. and
Hemmings, B.A. (1995) Nature 378, 785^789.
[11] Saito, Y., Vandenheede, J.R. and Cohen, P. (1994) Biochem. J.
303, 27^31.
[12] Stambolic, V. and Woodgett, J.R. (1994) Biochem. J. 303, 701^
704.
[13] Sutherland, C., Leighton, I.A. and Cohen, P. (1993) Biochem. J.
296, 15^19.
[14] Sutherland, C. and Cohen, P. (1994) FEBS Lett. 338, 37^42.
[15] Van Weeren, P.C., de Bruyn, K.M.T., de Vries-Smits, A.M.M.,
van Lint, J. and Burgering, B.M.T. (1998) J. Biol. Chem. 273,
13150^13156.
[16] Cross, D.A.E., Alessi, D.R., Vandenheede, J.R., McDowell,
H.E., Hundal, H.S. and Cohen, P. (1994) Biochem. J. 303, 21^26.
[17] Eldar-Finkelman, H., Seger, R., Vandenheede, J.R. and Krebs,
E.G. (1995) J. Biol. Chem. 270, 987^990.
[18] Barthel, A., Nakatani, K., Dandekar, A.A. and Roth, R.A.
(1998) Biochem. Biophys. Res. Commun. 243, 509^513.
[19] Cohen, P. (1999) Curr. Opin. Chem. Biol. 3, 459^465.
[20] Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T. and Saltiel, A.
(1995) J. Biol. Chem. 270, 27489^27494.
[21] Favata, M.F., Horiuchi, K.Y., Manos, E.J., Daulerio, A.J.,
Stradley, D.A., Feeser, W.S., Van Dyk, D.E., Pitts, W.J., Earl,
R.A., Hobbs, F., Copelands, R.A., Magolda, R.L., Scherle, P.A.
and Trzaskos, J.M. (1998) J. Biol. Chem. 273, 18623^18632.
[22] Walker, K.S., Deak, M., Paterson, A., Hudson, K., Cohen, P.
and Alessi, D.R. (1998) Biochem. J. 331, 299^308.
[23] Dalby, K.N., Morrice, N., Caudwell, F.B., Avruch, J. and Co-
hen, P. (1998) J. Biol. Chem. 273, 1496^1505.
[24] Bradford, M.M. (1976) Anal. Biochem. 72, 248^254.
[25] Alessi, D.R., Caudwell, F.B., Andjelkovic, M., Hemmings, B.A.
and Cohen, P. (1996) FEBS Lett. 399, 333^338.
[26] Shaw, M., Cohen, P. and Alessi, D.R. (1997) FEBS Lett. 416,
307^311.
[27] Shaw, M., Cohen, P. and Alessi, D.R. (1998) Biochem. J. 336,
241^246.
[28] Deak, M., Clifton, A.D., Lucocq, J.M. and Alessi, D.R. (1998)
EMBO J. 17, 4426^4441.
[29] Chen, R.H., Sarnecki, C. and Blenis, J. (1992) Mol. Cell. Biol.
12, 915^927.
FEBS 22869 4-11-99
M. Shaw, P. Cohen/FEBS Letters 461 (1999) 120^124124
